Literature DB >> 31313098

Camrelizumab: First Global Approval.

Anthony Markham1, Susan J Keam2.   

Abstract

Camrelizumab (AiRuiKa™), a programmed cell death 1 (PD-1) inhibitor being developed by Jiangsu Hengrui Medicine Co. Ltd, recently received conditional approval in China for the treatment of relapsed or refractory classical Hodgkin lymphoma. The drug is also being investigated as a treatment for various other malignancies, including B cell lymphoma, oesophageal squamous cell carcinoma, gastric/gastroesophageal junction cancer, hepatocellular carcinoma, nasopharyngeal cancer and non-squamous, non-small cell lung cancer. This article summarizes the milestones in the development of camrelizumab leading to this first approval for classical Hodgkin lymphoma.

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31313098     DOI： 10.1007/s40265-019-01167-0

Source DB:  PubMed          Journal:  Drugs        ISSN： 0012-6667            Impact factor:   9.546


  56 in total

Review 1.  [Special tumor entities in the head and neck region : Nasopharyngeal carcinoma, salivary gland, and thyroid cancer].

Authors:  Henrike B Zech; Christian S Betz
Journal:  HNO       Date:  2022-03-08       Impact factor: 1.284

2.  Cost-effectiveness of camrelizumab versus chemotherapy for the treatment of advanced or metastatic esophageal squamous cell carcinoma.

Authors:  Lizong Li; Xuemei Liu; Jing Huang; Yi Liu; Lin Huang; Yufei Feng
Journal:  J Gastrointest Oncol       Date:  2022-02

3.  A Phase 2 Study of Camrelizumab for Advanced Hepatocellular Carcinoma: Two-Year Outcomes and Continued Treatment beyond First RECIST-Defined Progression.

Authors:  Zhenggang Ren; Shukui Qin; Zhiqiang Meng; Zhendong Chen; Xiaoli Chai; Jianping Xiong; Yuxian Bai; Lin Yang; Hong Zhu; Weijia Fang; Xiaoyan Lin; Xiaoming Chen; Enxiao Li; Linna Wang; Ping Yan; Jianjun Zou
Journal:  Liver Cancer       Date:  2021-06-30       Impact factor: 11.740

Review 4.  Generation, secretion and degradation of cancer immunotherapy target PD-L1.

Authors:  Dan-Dan Shen; Ya-Ping Bi; Jing-Ru Pang; Li-Juan Zhao; Long-Fei Zhao; Ya Gao; Bo Wang; Hui-Min Liu; Ying Liu; Ning Wang; Yi-Chao Zheng; Hong-Min Liu
Journal:  Cell Mol Life Sci       Date:  2022-07-11       Impact factor: 9.207

5.  An Efficient UPLC-MS/MS Method Established to Detect Relugolix Concentration in Rat Plasma.

Authors:  Liying Xing; Ya-Nan Liu; Hongye Yao; Tingting Wang; Fuchen Xie; Shunbin Luo; Pingping Luo; Shengling Tang
Journal:  Front Pharmacol       Date:  2022-06-16       Impact factor: 5.988

Review 6.  Evidence-Based Management of Uterine Fibroids With Botanical Drugs-A Review.

Authors:  Masita Arip; Vi Lien Yap; Mogana Rajagopal; Malarvili Selvaraja; K Dharmendra; Sasikala Chinnapan
Journal:  Front Pharmacol       Date:  2022-06-22       Impact factor: 5.988

7.  Salvage camrelizumab plus apatinib for relapsed esophageal neuroendocrine carcinoma after esophagectomy: a case report and review of the literature.

Authors:  Lei Liu; Yuanyuan Liu; Longbo Gong; Miao Zhang; Wenbin Wu
Journal:  Cancer Biol Ther       Date:  2020-10-23       Impact factor: 4.742

8.  Combined immunotherapy and targeted treatment for primary alveolar soft part sarcoma of the lung: case report and literature review.

Authors:  Hui Su; Chao Yu; Xuezhen Ma; Qingcui Song
Journal:  Invest New Drugs       Date:  2021-03-25       Impact factor: 3.850

9.  Post-translational regulations of PD-L1 and PD-1: Mechanisms and opportunities for combined immunotherapy.

Authors:  Xiaoming Dai; Yang Gao; Wenyi Wei
Journal:  Semin Cancer Biol       Date:  2021-04-05       Impact factor: 17.012

10.  N-glycosylation of PD-1 promotes binding of camrelizumab.

Authors:  Kefang Liu; Shuguang Tan; Wanjun Jin; Jiawei Guan; Qingling Wang; Huan Sun; Jianxun Qi; Jinghua Yan; Yan Chai; Zhongfu Wang; Chuxia Deng; George F Gao
Journal:  EMBO Rep       Date:  2020-10-15       Impact factor: 9.071
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.